These graphs compare the performance of the biotech stocks for all of 2023 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.

Year-to-date money raised in public, private and other financings of biopharma companies.

Biopharma money raised to-date and by month in 2023, including public, private and other financings.

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 180, Aardvark, ABM, Orchard, Taiho.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Assertio, Catalent, Evox, Fuji, Galapagos, Ionis, Kiora, Mind, Mithra, Novartis, Zydus.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aravive, Arbele, Areteia, Asklepios, Bolt, Cage, Celsius, CNS, Perfuse, Regeneron, Ultimovacs, Vertex, Xylocor.

Biopharmas raising money in public or private financings, including: Blue Water, Innocan.

New hires and promotions in the biopharma industry, including: Deciphera, Structure, Terns, Xilio.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Irhythm Technologies, Quanta Dialysis Technologies.